Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GWPHNASDAQ:ONCNASDAQ:RPRXNASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGWPHGW Pharmaceuticals$218.96$218.59$87.07▼$219.57$6.86B2.15899,771 shsN/AONCBeOne Medicines$257.51+4.2%$245.88$141.31▼$287.88$27.08B0.3301,400 shs450,660 shsRPRXRoyalty Pharma$35.40+1.5%$33.20$24.05▼$35.71$19.60B0.483.63 million shs3.36 million shsSMMTSummit Therapeutics$20.39-0.8%$23.65$6.78▼$36.91$15.27B-1.063.61 million shs2.76 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGWPHGW Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ONCBeOne Medicines+4.22%-2.61%+6.66%+2.81%+25,750,999,900.00%RPRXRoyalty Pharma+1.55%+0.85%+9.09%+4.86%+31.55%SMMTSummit Therapeutics-0.83%+2.21%-21.12%+0.74%+157.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGWPHGW PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AONCBeOne Medicines1.3613 of 5 stars2.50.00.00.02.21.70.6RPRXRoyalty Pharma4.8386 of 5 stars3.61.03.33.73.51.72.5SMMTSummit Therapeutics3.2961 of 5 stars4.43.00.00.03.21.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGWPHGW Pharmaceuticals 0.00N/AN/AN/AONCBeOne Medicines 3.00Buy$319.0023.88% UpsideRPRXRoyalty Pharma 3.25Buy$47.3333.71% UpsideSMMTSummit Therapeutics 2.77Moderate Buy$35.0972.10% UpsideCurrent Analyst Ratings BreakdownLatest GWPH, ONC, SMMT, and RPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025SMMTSummit TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell6/11/2025SMMTSummit TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$12.006/2/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$40.005/16/2025RPRXRoyalty PharmaMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$51.005/8/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$312.00 ➝ $311.005/8/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$348.00 ➝ $350.005/8/2025SMMTSummit TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/2/2025SMMTSummit TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $41.004/28/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.004/28/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$312.00 ➝ $312.004/28/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$40.00 ➝ $40.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGWPHGW Pharmaceuticals$311.33M22.05$0.01 per share18,588.22$23.48 per share9.33ONCBeOne Medicines$3.81B7.41N/AN/A$34.10 per share7.55RPRXRoyalty Pharma$2.26B8.79$4.26 per share8.31$17.56 per share2.02SMMTSummit Therapeutics$700K21,632.92N/AN/A$0.53 per share38.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGWPHGW Pharmaceuticals-$9.02M-$0.24N/A608.22N/A-11.05%-7.46%-6.13%N/AONCBeOne Medicines-$644.79M-$3.72N/A362.69N/A-9.40%-7.55%-4.42%N/ARPRXRoyalty Pharma$858.98M$1.8519.147.281.7948.23%24.71%13.87%8/6/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$0.34N/AN/AN/AN/A-62.87%-51.61%8/5/2025 (Estimated)Latest GWPH, ONC, SMMT, and RPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025RPRXRoyalty Pharma$0.99$1.06+$0.07$0.41$724.69 million$839.00 million5/7/2025Q1 2025ONCBeOne Medicines-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billion5/1/2025Q1 2025SMMTSummit Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGWPHGW PharmaceuticalsN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ARPRXRoyalty Pharma$0.882.49%N/A47.57%5 YearsSMMTSummit TherapeuticsN/AN/AN/AN/AN/ALatest GWPH, ONC, SMMT, and RPRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/21/2025RPRXRoyalty Pharmaquarterly$0.222.7%5/16/20255/16/20256/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGWPHGW Pharmaceuticals0.015.134.31ONCBeOne Medicines0.051.961.71RPRXRoyalty Pharma0.681.561.56SMMTSummit TherapeuticsN/A10.6310.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGWPHGW Pharmaceuticals81.00%ONCBeOne Medicines48.55%RPRXRoyalty Pharma54.35%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipGWPHGW Pharmaceuticals3.10%ONCBeOne Medicines6.62%RPRXRoyalty Pharma18.90%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGWPHGW Pharmaceuticals1,16131.35 millionN/AOptionableONCBeOne Medicines11,000109.60 million102.34 millionN/ARPRXRoyalty Pharma80562.24 million455.98 millionOptionableSMMTSummit Therapeutics110742.67 million112.14 millionOptionableGWPH, ONC, SMMT, and RPRX HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 23 at 12:26 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 22 at 10:00 AM | prnewswire.comWorld Equity Group Inc. Sells 14,062 Shares of Summit Therapeutics PLC (NASDAQ:SMMT)June 22 at 4:40 AM | marketbeat.comGAMMA Investing LLC Purchases 15,331 Shares of Summit Therapeutics PLC (NASDAQ:SMMT)June 21 at 3:18 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Downgraded to "Sell" Rating by Wall Street ZenJune 21 at 2:54 AM | marketbeat.comSummit Therapeutics PLC (NASDAQ:SMMT) Shares Sold by Five Pine Wealth ManagementJune 20, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 18, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 17, 2025 | prnewswire.comSummit Therapeutics SMMT Sees Institutional Growth on Nasdaq CompositeJune 17, 2025 | kalkinemedia.comQ2 Earnings Forecast for SMMT Issued By Leerink PartnrsJune 17, 2025 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 16, 2025 | accessnewswire.comAnalysts Offer Predictions for SMMT Q2 EarningsJune 16, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit ...June 15, 2025 | bakersfield.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 15, 2025 | globenewswire.comSummit Therapeutics (NASDAQ:SMMT) Upgraded at Leerink PartnrsJune 14, 2025 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 13, 2025 | accessnewswire.comPolianta Ltd Takes $1.17 Million Position in Summit Therapeutics Inc. (NASDAQ:SMMT)June 13, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Trading Up 5.1% - Time to Buy?June 12, 2025 | marketbeat.comThese 24 Stocks Are Ripe for a Short SqueezeJune 12, 2025 | schaeffersresearch.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 12, 2025 | prnewswire.comSummit Therapeutics (NASDAQ:SMMT) Rating Increased to Strong Sell at Leerink PartnrsJune 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsBy Leo Miller | May 27, 2025View 3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsRKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernPalantir Soars on Government Deals as Valuation Debate LingersBy Chris Markoch | June 3, 2025View Palantir Soars on Government Deals as Valuation Debate LingersAdvance Auto Parts: Did Earnings Defuse Tariff Concerns?By Gabriel Osorio-Mazilli | May 28, 2025View Advance Auto Parts: Did Earnings Defuse Tariff Concerns?GWPH, ONC, SMMT, and RPRX Company DescriptionsGW Pharmaceuticals NASDAQ:GWPHGW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.BeOne Medicines NASDAQ:ONC$257.51 +10.43 (+4.22%) As of 06/23/2025 04:00 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Royalty Pharma NASDAQ:RPRX$35.40 +0.54 (+1.55%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$35.70 +0.31 (+0.86%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Summit Therapeutics NASDAQ:SMMT$20.39 -0.17 (-0.83%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$20.79 +0.40 (+1.96%) As of 06:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
